(Q43814142)

27 November 2017

title

Management of CNS-related Disease Manifestations in Patients With Tuberous Sclerosis Complex (English)

1 reference

27 November 2017

1 reference

Darcy A Krueger

1

1 reference

27 November 2017

language of work or name

1 reference

1 October 2013

1 reference

Current treatment options in neurology

27 November 2017

published in

1 reference

27 November 2017

volume

15

1 reference

27 November 2017

issue

5

1 reference

27 November 2017

page(s)

618-633

1 reference

Identification and characterization of the tuberous sclerosis gene on chromosome 16

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0249-2

Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0249-2

Rheb binds and regulates the mTOR kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0249-2

Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0249-2

Rapamycin causes regression of astrocytomas in tuberous sclerosis complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0249-2

Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0249-2

Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0249-2

Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0249-2

Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0249-2

Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0249-2

Efficacy and safety of sirolimus in lymphangioleiomyomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0249-2

Topical 0.1% rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: a pilot study of four patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0249-2

Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0249-2

Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: a double-blind, randomized, controlled trial to evaluate the safety and efficacy of topically applied rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0249-2

Everolimus: a challenging drug in the treatment of multifocal inoperable cardiac rhabdomyoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0249-2

Regression of a cardiac rhabdomyoma in a patient receiving everolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0249-2

Everolimus treatment of refractory epilepsy in tuberous sclerosis complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0249-2

Tsc1 mutant neural stem/progenitor cells exhibit migration deficits and give rise to subependymal lesions in the lateral ventricle

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0249-2

Loss of Tsc2 in radial glia models the brain pathology of tuberous sclerosis complex in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0249-2

Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0249-2

CT and MR imaging of cerebral tuberous sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0249-2

Neuroimaging of tuberous sclerosis: spectrum of pathologic findings and frontiers in imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0249-2

Biological behavior and tumorigenesis of subependymal giant cell astrocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0249-2

Prevalence of subependymal giant cell tumors in patients with tuberous sclerosis and a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0249-2

Congenital subependymal giant cell astrocytoma: clinical considerations and expression of radial glial cell markers in giant cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0249-2

Neonatal subependymal giant cell astrocytoma: new case and review of literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0249-2

Brain tumors in tuberous sclerosis. A clinicopathologic study of the Mayo Clinic experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0249-2

Subependymal giant cell astrocytoma (SEGA): Is it an astrocytoma? Morphological, immunohistochemical and ultrastructural study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0249-2

Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0249-2

Tuberous sclerosis complex: a review of neurological aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0249-2

Consensus clinical guidelines for the assessment of cognitive and behavioural problems in Tuberous Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0249-2

The Ketogenic Diet for the Treatment of Epilepsy: A Challenge for Nutritional Neuroscientists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0249-2

Tuberous sclerosis complex and the ketogenic diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0249-2

Low glycemic index treatment for epilepsy in tuberous sclerosis complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0249-2

Nursing implications for the lifelong management of tuberous sclerosis complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0249-2

Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0249-2

A mouse model of tuberous sclerosis: neuronal loss of Tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity, and limited survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0249-2

Rapamycin reduces seizure frequency in tuberous sclerosis complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0249-2

The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0249-2

Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0249-2

The ketogenic diet inhibits the mammalian target of rapamycin (mTOR) pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0249-2

Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0249-2

Rapamycin for treating Tuberous sclerosis and Autism spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0249-2

Evidence-based guideline update: medical treatment of infantile spasms. Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0249-2

Vigabatrin in the treatment of childhood epilepsy: a retrospective chart review of efficacy and safety profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0249-2

Vigabatrin for childhood partial-onset epilepsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0249-2

Vigabatrin retinopathy in an Irish cohort: lack of correlation with dose.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0249-2

Taurine deficiency is a cause of vigabatrin-induced retinal phototoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0249-2

Levetiracetam as adjunctive antiepileptic therapy for patients with tuberous sclerosis complex: a retrospective open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0249-2

Lamotrigine therapy of epilepsy in tuberous sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0249-2

Current management of tuberous sclerosis complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0249-2

Molecular activity of sirolimus and its possible application in tuberous sclerosis treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0249-2

Management of subependymal giant cell tumors in tuberous sclerosis complex: the neurosurgeon's perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0249-2

Subependymal giant-cell astrocytomas in pediatric tuberous sclerosis disease: when should we operate?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0249-2

The management of subependymal giant cell tumors in tuberous sclerosis: a clinician's perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0249-2

Outcomes of resecting subependymal giant cell astrocytoma (SEGA) among patients with SEGA-related tuberous sclerosis complex: a national claims database analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0249-2

Everolimus for tumor recurrence after surgical resection for subependymal giant cell astrocytoma associated with tuberous sclerosis complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0249-2

Tuberous sclerosis complex: a review of the management of epilepsy with emphasis on surgical aspects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0249-2

Refractory epilepsy in tuberous sclerosis: vagus nerve stimulation with or without subsequent resective surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0249-2

21 January 2018

1 reference

12 December 2020

Psychiatric comorbidity and treatment response in patients with tuberous sclerosis complex

1 reference

12 December 2020

Prevalence of tuberous sclerosis estimated by capture-recapture analysis.

1 reference

12 December 2020

Treatment of facial angiofibromas with topical application of oral rapamycin solution (1mgmL(-1) ) in two patients with tuberous sclerosis

1 reference

12 December 2020

Epilepsy surgery in children with tuberous sclerosis complex: presurgical evaluation and outcome

1 reference

12 December 2020

Epilepsy surgery for children with tuberous sclerosis complex

1 reference

12 December 2020

Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease

1 reference

12 December 2020

Subependymal giant cell astrocytoma in children with tuberous sclerosis

1 reference

12 December 2020

Managing epilepsy in tuberous sclerosis complex

1 reference

12 December 2020

The effects of the ketogenic diet in refractory partial seizures with reference to tuberous sclerosis

1 reference

12 December 2020

10.1007/S11940-013-0249-2

Identifiers

DOI

1 reference

Dimensions Publication ID

27 November 2017

1037623940

0 references

1 reference